Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZD7288
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intrathecal
01
Overview
ZD7288 is a small molecule pyrimidine derivative that serves as a potent and widely used pharmacological tool for blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. It inhibits the hyperpolarization-activated current (Ih), also known as the "funny" current (If) in the heart, which is critical for pacemaker activity and neuronal excitability. While ZD7288 is effective across all HCN subunits (HCN1-4), it is considered relatively non-specific and has been reported to exhibit off-target effects on voltage-gated sodium and calcium channels at higher concentrations. Originally developed by Zeneca (now AstraZeneca), the compound is primarily utilized in electrophysiological and developmental biology research, such as investigating the role of HCN channels in cardiac progenitor cell metabolism and ventricular chamber development.
- Other names
- 4-Ethylphenylamino-1,2-dimethyl-6-methylaminopyrimidinium chlorideZD 7288ZD7288ZD-7288
02
Targets
NaV (Voltage-gated sodium channels)HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)HCN2 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2)HCN3 (Hyperpolarization-activated cyclic nucleotide-gated channel 3)HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4)
Beyond the preview
Go deeper on ZD7288.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZD7288.